|
시장보고서
상품코드
1935298
P2X7 수용체 길항제 시장 : 약물별, 용도별, 지역별P2X7 Receptor Antagonists Market, By Drugs, By Application, By Geography |
||||||
P2x7 수용체 길항제 시장은 2026년에 1억 3,520만 달러로 추정되며, 2033년까지 4억 3,800만 달러에 달할 것으로 예측됩니다. 2026년부터 2033년까지 CAGR 18.3%로 성장할 전망입니다.
| 보고서 내용 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 1억 3,520만 달러 |
| 과거 데이터 대상 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 예측 기간 2026-2033년 CAGR: | 18.30% | 2033년 예측치: | 4억 3,800만 달러 |
P2X7 수용체 길항제는 아직 개발 단계에 있으며, 시장 출시를 위해서는 규제 당국의 승인이 필요합니다. 제조업체는 미국 식품의약국(FDA)에 임상시험계획(IND)을 제출해야 합니다. 모든 의약품은 FDA가 정한 승인 절차를 거쳐야 합니다. P2X7 길항제 역시 다른 신약과 마찬가지로 임상시험계획신청(IND)을 제출한 후 모든 임상시험을 거치게 됩니다. 그러나 제약사들은 엄격한 규제 승인 절차로 인해 이러한 약물을 시장에 출시하는 데 있어 몇 가지 어려움에 직면해 있습니다. 이러한 요인은 세계 P2X7 수용체 길항제 시장 및 세계 P2X7 수용체 길항제 시장의 성장에 영향을 미치는 요인으로 간주됩니다.
시장 역학
P2X7 수용체 길항제 카테고리는 현재 효과적인 치료제가 존재하지 않기 때문에 매우 수익성이 높은 분야입니다. 주요 기업들은 이 카테고리의 의약품 연구개발에 투자하고 있으며, 특허 보호를 통해 시장 기업들이 고수익을 올릴 수 있도록 지원할 것으로 예상됩니다. 주요우울장애, 기분장애, 만성 통증, 염증 등의 질환 및 증상은 높은 유병률을 보이고 있으며, 그 발생률도 증가하는 추세입니다. 영국 국민보건서비스 디지털(NHS Digital)에 따르면, 2016년 항우울제 처방이 가장 큰 폭으로 증가해 우울장애가 확산되고 있음을 시사합니다. P2X7 수용체 길항제가 출시되면 승인 대상 질환이나 적응증에서 상당한 시장 점유율을 확보할 수 있습니다. 제약사들도 AKP-23494954/RQ-00466479(아사히카세이/라쿠오리아제약)와 같은 혁신적인 약물을 개발하여 P2X7 길항제 카테고리를 추진하고 있습니다. 이러한 요인들은 예측 기간 동안 세계 P2X7 수용체 길항제 시장의 성장을 뒷받침할 것으로 예상됩니다.
본 조사의 주요 특징
- 이 보고서는 P2X7 수용체 길항제(P2X7 receptor antagonists) 시장에 대한 상세한 분석을 제공하며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모와 연평균 성장률(CAGR)을 제시합니다.
- 또한, 다양한 부문의 잠재적 수익기회를 확인하고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 또는 승인, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 보고서는 회사 개요, 재무 실적, 제품 포트폴리오, 지리적 확장, 유통 전략, 주요 개발 및 전략 등 다양한 매개 변수를 기반으로 세계 P2X7 수용체 길항제 시장의 주요 업체를 프로파일링합니다.
- 이 보고서는 마케팅 담당자와 기업 경영진이 기술 업그레이드, 시장 확대, 마케팅 전략을 통해 향후 제품 출시에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 P2X7 수용체 길항제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 P2X7 수용체 길항제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 P2X7 수용체 길항제 시장 : 약물별, 2026-2033년
제5장 세계의 P2X7 수용체 길항제 시장 : 용도별, 2026-2033년
제6장 세계의 P2X7 수용체 길항제 시장 : 지역별, 2026-2033년
제7장 경쟁 구도
제8장 섹션
KSMP2x7 Receptor Antagonists Market is estimated to be valued at USD 135.2 Mn in 2026 and is expected to reach USD 438 Mn by 2033, growing at a compound annual growth rate (CAGR) of 18.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 135.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 18.30% | 2033 Value Projection: | USD 438 Mn |
P2X7 receptor antagonists are still in the developmental stage and will require regulatory approval for introduction into the market. Manufacturers need to file an Investigational New Drug Application (IND) with the U.S. Food & Drug Application (FDA). Every drug is required to go through the approval process set by the FDA. P2X7 antagonists will be going through all the clinical trials after filing an Investigational New Drug (IND) application as any other new drug. However, the pharmaceutical organizations face several challenges for introducing these medications in the market due to a stringent regulatory approval process. These factors are considered in global P2X7 receptor antagonist market and factors affecting global P2X7 receptor antagonist market growth.
Market Dynamics
P2X7 Receptor Antagonists drug category is highly lucrative, as no drug therapies are available in this category. Leading organizations are investing in research and development of drugs in this category, which is expected to help market players in generating high revenue using patent protection. Disease and conditions such as major depressive disorders, mood disorders, chronic pain, and inflammation are highly prevalent and their incidence is also increasing. According to National Health Service Digital (NHS Digital), U.K., antidepressants medications prescriptions observed the largest increase in 2016, indicating the prevalence of depressive disorders. If launched, P2X7 receptor antagonists will be capable of acquiring a significant amount of market share for the disease or indication for which they have been approved. Drug manufacturers are also advancing the P2X7 antagonist drug category by developing innovative drugs such as AKP-23494954/RQ-00466479 (Asahi Kasei/RaQualia Pharma). These factors are expected to support global P2X7 receptor antagonist market growth over the forecast period.
Key features of the study
- This report provides in-depth analysis of the P2X7 receptor antagonists market and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global P2X7 receptor antagonists market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
- Key companies covered as a part of this study include, Asahi Kasei Corporation, GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, Evotec AG, and RaQualia Pharma
- Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
- The global P2X7 receptor antagonists market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the P2X7 receptor antagonists market
Market Segmentation
- Drugs Insights (Revenue, USD Mn, 2026 - 2033)
- AKP-23494954/RQ-00466479
- EVT 401
- GSK1482160
- JNJ-55308942
- JNJ-54175446
- Others (e.g.- AZ11657312)
- Application Insights (Revenue, USD Mn, 2026 - 2033)
- Central Nervous System Disorders
- Immunological Disorders
- Others
- Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GlaxoSmithKline Plc
- Johnson & Johnson
- AstraZeneca Plc
- RaQualia Pharma
- Evotec AG
- Asahi Kasei Corporation
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drugs
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Pipeline Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- PEST Analysis
- Epidemiology
4. Global P2X7 Receptor Antagonists Market, By Drugs, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- AKP-23494954/RQ-00466479
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- EVT 401
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- GSK1482160
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- JNJ-55308942
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- JNJ-54175446
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others (e.g.- AZ11657312)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global P2X7 Receptor Antagonists Market, By Application, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Central Nervous System Disorders
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Immunological Disorders
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global P2X7 Receptor Antagonists Market, By Region, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- South Africa
- North Africa
- Central Africa
7. Competitive Landscape
- Company Profiles
- Asahi Kasei Corporation
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Evotec AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- RaQualia Pharma
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Asahi Kasei Corporation
8. Section
- References
- Research Methodology
- About us and Sales Contact
(주말 및 공휴일 제외)
